Abeona Therapeutics Inc. ABEO
5.40
(0.03)
(0.55%)
as of 25 Sep
- Market cap
- $303.8M
- P/E
- 0.0×
Follow ABEO
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
75.90% | 70.05% | 70.99% | (43.13%) | |
| 46.83% | 43.34% | 44.41% | (29.54%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
40.31% | 40.37% | 40.70% | (41.95%) | |
Average Days of Receivables |
0.00 | 261.08 | 135.74 | 139.25 | |
Free Cash Flow per Share |
(1.52) | (1.59) | (1.51) | (1.43) | |
Free Cash Flow |
(82.36) | (84.30) | (85.24) | (81.53) | |
Capital Expenditures |
(7.43) | (7.97) | (7.51) | (5.09) | |
Piotroski F-Score |
5.00 | 5.00 | 5.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(18.81%) | (20.59%) | (23.46%) | (26.37%) | |
Accounts Receivable Turnover |
0.00 | 2.24 | 4.33 | 4.50 | |
Accounts Payable Turnover |
0.65 | 0.41 | 0.94 | 1.63 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 1.95 | |
Average Days of Payables |
760.67 | 1,244.91 | 348.97 | 130.02 | |
Days of Inventory on Hand |
622.45 | 866.82 | 518.95 | 257.13 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 285.60% | 146.49% | 98.40% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 692.70% | 414.34% | 283.31% | |
Share Based Compensation of Revenue |
0.00% | 114.82% | 71.47% | 44.65% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.91) | (1.07) | (1.18) | 1.22 | |
Depreciation/Fixed assets |
0.31 | 3.59 | 0.34 | 0.36 | |
Capex/Depreciation |
(2.29) | (2.24) | (2.08) | (1.38) | |
Revenue per Share |
0.00 | 0.18 | 0.32 | 0.45 | |
Operating CF per Share |
(1.38) | (1.44) | (1.37) | (1.34) | |
Capex per Share |
(0.14) | (0.15) | (0.13) | (0.09) | |
Capex to Sales |
0.00 | 0.85 | 0.42 | 0.20 | |
Net Profit Margin |
0.00% | 758.23% | 366.61% | (242.62%) |
Columns are period end dates